Market Overview

VIVUS to Present at the 2013 JP Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 4, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, Chief Executive Officer, will present an overview of the Company at the 31st Annual JP Morgan Healthcare Conference.

The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Monday, January 7, 2013 at 2:30 p.m. PST. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets.  Qsymia is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2011, and periodic reports filed with the Securities and Exchange Commission.
 

CONTACT: VIVUS, Inc. Timothy E. Morris Chief Financial Officer morris@vivus.com Media Relations: GolinHarris Ashley Buford abuford@golinharris.com 212-373-6045 Investor Relations: The Trout Group Brian Korb bkorb@troutgroup.com 646-378-2923
 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters